Diagnosis and Treatment of Major Depressive Disorder

Neurologic Clinics

Volumn 29, Issue 1, 2011, Pages 177-193

  Soleimani, Laili ^a   Lapidus, Kyle A B ^a   Iosifescu, Dan V ^a,b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antidepressant treatments; Comorbid medical illness; Comorbid neurologic illness; Major depressive disorder; Pharmacotherapies; Psychotherapies; Somatic treatments

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DESVENLAFAXINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; ISOCARBOXAZID; MAPROTILINE; MIRTAZAPINE; NEUROPEPTIDE; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTEIN BCL 2; PROTRIPTYLINE; SELEGILINE; SERTRALINE; TRANYLCYPROMINE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; ANTICHOLINERGIC EFFECT; ANXIETY; APPETITE; APPETITE DISORDER; BACKACHE; BEREAVEMENT; BIPOLAR DISORDER; BIPOLAR I DISORDER; BLURRED VISION; CARDIOTOCOGRAPHY; CARDIOTOXICITY; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CONSTIPATION; DEPRESSION; DIAPHORESIS; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRUG EFFECT; ENVIRONMENTAL FACTOR; ENVIRONMENTAL STRESS; FATIGUE; GUILT; HEADACHE; HEART CONDUCTION; HEART PALPITATION; HEREDITY; HUMAN; HYPERTENSIVE CRISIS; HYPERTHERMIA; HYPOTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; IRRITABILITY; MAJOR DEPRESSION; MANIA; MEMORY DISORDER; MONOAMINERGIC NERVE; MULTIPLE SCLEROSIS; MUSCLE TONE; NAUSEA; NERVOUSNESS; NEUROENDOCRINE SYSTEM; ORAL PARESTHESIA; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PARKINSON DISEASE; PATIENT SAFETY; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIC TREATMENT; PSYCHOTHERAPY; PYRIDOXINE DEFICIENCY; RATING SCALE; RECOMMENDED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SEDATION; SEROTONIN SYNDROME; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUS TACHYCARDIA; STROKE; SUICIDAL IDEATION; TACHYCARDIA; TREMOR; URINE RETENTION; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PSYCHOSOMATIC MEDICINE; PSYCHOTHERAPY;

EID: 78650251138     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2010.10.010     Document Type: Review

References (87)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders fourth edition (text revision) DSM-IV-TR 2000, American Psychiatric Association, Washington, DC.
2. Kessler R.C., Chiu W.T., Demler O., et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62(6):617-627.
3. Weissman M.M., Olfson M. Depression in women: implications for health care research. Science 1995, 269(5225):799-801.
4. Pincus H.A., Zarin D.A., Tanielian T.L., et al. Psychiatric patients and treatments in 1997: findings from the American Psychiatric Practice Research Network. Arch Gen Psychiatry 1999, 56(5):441-449.
5. Mental illness in general health practice: an international study 1995, Wiley, New York. T.B. Ustun, N. Sartorius (Eds.).
6. Teresi J., Abrams R., Holmes D., et al. Prevalence of depression and depression recognition in nursing homes. Soc Psychiatry Psychiatr Epidemiol 2001, 36(12):613-620.
7. World Psychiatric Association. International Committee for Diagnosis and Treatment of Depression. Educational program on depressive disorders, module II. Depressive disorders in physical illness, part I: 2. New York: NCM Publishers; 1998.
8. Manji H.K., Drevets W.C., Charney D.S. The cellular neurobiology of depression. Nat Med 2001, 7(5):541-547.
9. Charney D.S., Manji H.K. Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE 2004, 2004(225):re5.
10. Mann J.J., Currier D. Effects of genes and stress on the neurobiology of depression. Int Rev Neurobiol 2006, 73:153-189.
11. Nestler E.J., Barrot M., DiLeone R.J., et al. Neurobiology of depression. Neuron 2002, 34(1):13-25.
12. Rush A.J., Trivedi M.H., Ibrahim H.M., et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003, 54(5):573-583.
13. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr 1960, 23:56-62.
14. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967, 6(4):278-296.
15. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
16. Beck A.T., Ward C.H., Mendelson M., et al. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
17. Yesavage J.A., Brink T.L., Rose T.L., et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982, 17(1):37-49.
18. Hybels C.F., Blazer D.G., Pieper C.F., et al. Profiles of depressive symptoms in older adults diagnosed with major depression: latent cluster analysis. Am J Geriatr Psychiatry 2009, 17(5):387-396.
19. Mann J.J., Apter A., Bertolote J., et al. Suicide prevention strategies: a systematic review. JAMA 2005, 294(16):2064-2074.
20. Bruce M.L., Leaf P.J. Psychiatric disorders and 15-month mortality in a community sample of older adults. Am J Public Health 1989, 79(6):727-730.
21. Iosifescu D.V. Treating depression in the medically ill. Psychiatr Clin North Am 2007, 30(1):77-90.
22. Hackett M.L., Yapa C., Parag V., et al. Frequency of depression after stroke: a systematic review of observational studies. Stroke 2005, 36(6):1330-1340.
23. House A., Knapp P., Bamford J., et al. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke 2001, 32(3):696-701.
24. Robinson R.G. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry 2003, 54(3):376-387.
25. Robinson R.G., Price T.R. Post-stroke depressive disorders: a follow-up study of 103 patients. Stroke 1982, 13(5):635-641.
26. Robinson R.G., Schultz S.K., Castillo C., et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000, 157(3):351-359.
27. Wiart L., Petit H., Joseph P.A., et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000, 31(8):1829-1832.
28. Whyte E.M., Mulsant B.H. Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry 2002, 52(3):253-264.
29. Robinson R.G., Jorge R.E., Moser D.J., et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA 2008, 299(20):2391-2400.
30. Sadovnick A.D., Remick R.A., Allen J., et al. Depression and multiple sclerosis. Neurology 1996, 46(3):628-632.
31. Ziemssen T. Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci 2009, 277(Suppl 1):S37-S41.
32. Kargiotis O., Geka A., Rao J.S., et al. Quality of life in multiple sclerosis: effects of current treatment options. Int Rev Psychiatry 2010, 22(1):67-82.
33. Patten S.B., Beck C.A., Williams J.V., et al. Major depression in multiple sclerosis: a population-based perspective. Neurology 2003, 61(11):1524-1527.
34. Wilken J.A., Sullivan C. Recognizing and treating common psychiatric disorders in multiple sclerosis. Neurologist 2007, 13(6):343-354.
35. Treadaway K., Cutter G., Salter A., et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009, 256(4):568-576.
36. Mohr D.C., Goodkin D.E., Likosky W., et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler 1996, 2(5):222-226.
37. Mohr D.C., Goodkin D.E., Likosky W., et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997, 54(5):531-533.
38. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 2005, 11(3):328-337.
39. Mohr D.C., Goodkin D.E. Treatment of depression in multiple sclerosis: review and meta-analysis. Clin Psychol Sci Pract 1999, 6:1-9.
40. Sindrup S.H., Jensen T.S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999, 83(3):389-400.
41. Minden S.L. Mood disorders in multiple sclerosis: diagnosis and treatment. J Neurovirol 2000, 6(Suppl 2):S160-S167.
42. Ravina B., Camicioli R., Como P.G., et al. The impact of depressive symptoms in early Parkinson disease. Neurology 2007, 69(4):342-347.
43. Cummings J.L. Depression and Parkinson's disease: a review. Am J Psychiatry 1992, 149(4):443-454.
44. Mayberg H.S., Solomon D.H. Depression in Parkinson's disease: a biochemical and organic viewpoint. Adv Neurol 1995, 65:49-60.
45. Remy P., Doder M., Lees A., et al. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128(Pt 6):1314-1322.
46. Andersen J., Aabro E., Gulmann N., et al. Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with l-DOPA. Acta Neurol Scand 1980, 62(4):210-219.
47. Laitinen L. Desipramine in treatment of Parkinson's disease. A placebo-controlled study. Acta Neurol Scand 1969, 45(1):109-113.
48. Goetz C.G., Tanner C.M., Klawans H.L. Bupropion in Parkinson's disease. Neurology 1984, 34(8):1092-1094.
49. Lemke M.R., Brecht H.M., Koester J., et al. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 2005, 17(2):214-220.
50. Devos D., Dujardin K., Poirot I., et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008, 23(6):850-857.
51. Barone P., Scarzella L., Marconi R., et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006, 253(5):601-607.
52. Watanabe N., Omori I.M., Nakagawa A., et al. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. J Clin Psychiatry 2008, 69(9):1404-1415.
53. Trivedi M.H., Rush A.J., Wisniewski S.R., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163(1):28-40.
54. Papakostas G.I. The efficacy, tolerability, and safety of contemporary antidepressants. J Clin Psychiatry 2010, 71(Suppl E1):e03.
55. Fava M., Alpert J.E., Carmin C.N., et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 2004, 34(7):1299-1308.
56. Ravindran L.N., Stein M.B. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 2010, 71(7):839-854.
57. Stahl S.M., Grady M.M., Moret C., et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005, 10(9):732-747.
58. Atkinson J.H., Slater M.A., Williams R.A., et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain 1998, 76(3):287-296.
59. Snyder S.H., Yamamura H.I. Antidepressants and the muscarinic acetylcholine receptor. Arch Gen Psychiatry 1977, 34(2):236-239.
60. Moore A.R., O'Keeffe S.T. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999, 15(1):15-28.
61. Lavoie F.W., Gansert G.G., Weiss R.E. Value of initial ECG findings and plasma drug levels in cyclic antidepressant overdose. Ann Emerg Med 1990, 19(6):696-700.
62. Preskorn S.H., Simpson S. Tricyclic-antidepressant-induced delirium and plasma drug concentration. Am J Psychiatry 1982, 139(6):822-823.
63. Menza M., Dobkin R.D., Marin H., et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009, 72(10):886-892.
64. Quitkin F.M., et al. l-Deprenyl in atypical depressives. Arch Gen Psychiatry 1984, 41(8):777-781.
65. Quitkin F.M., Stewart J.W., McGrath P.J., et al. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988, 145(3):306-311.
66. Lane R., Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997, 17(3):208-221.
67. American Psychiatric Association American Psychiatric Association practice guidelines for the treatment of psychiatric disorders. Compendium 2006 2006, American Psychiatric Association, Arlington (VA), p. 1600, xii.
68. White N., Litovitz T., Clancy C. Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. J Med Toxicol 2008, 4(4):238-250.
69. Holm K.J., Markham A. Mirtazapine: a review of its use in major depression. Drugs 1999, 57(4):607-631.
70. Papakostas G.I., Shelton R.C., Smith J., et al. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 2007, 68(6):826-831.
71. Valenstein M., McCarthy J.F., Austin K.L., et al. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 2006, 163(7):1219-1225.
72. Bauer M., Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999, 19(5):427-434.
73. Aronson R., Offman H.J., Joffe R.T., et al. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996, 53(9):842-848.
74. Nierenberg A.A., Fava M., Trivedi M.H., et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006, 163(9):1519-1530. [quiz: 1665].
75. Papakostas G.I., Mischoulon D., Shyu I., et al. S-Adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 2010, 167(8):942-948.
76. Hollon S.D., Ponniah K. A review of empirically supported psychological therapies for mood disorders in adults. Depress Anxiety 2010, 27(10):891-932.
77. DeRubeis R.J., Hollon S.D., Amsterdam J.D., et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005, 62(4):409-416.
78. Paul S.M., Extein I., Calil H.M., et al. Use of ECT with treatment-resistant depressed patients at the National Institute of Mental Health. Am J Psychiatry 1981, 138(4):486-489.
79. Prudic J., Haskett R.F., Mulsant B., et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry 1996, 153(8):985-992.
80. Semkovska M., McLoughlin D.M. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry 2010, 68(6):568-577.
81. Zielinski R.J., Roose S.P., Devanand D.P., et al. Cardiovascular complications of ECT in depressed patients with cardiac disease. Am J Psychiatry 1993, 150(6):904-909.
82. George M.S., Lisanby S.P., Avery D., et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 2010, 67(5):507-516.
83. Slotema C.W., Blom J.D., Hoek H.W., et al. Should we expand the toolbox of psychiatric treatment methods to include repetitive transcranial magnetic stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry 2010, 71(7):873-884.
84. Rush A.J., Marangell L.B., Sackeim H.A., et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005, 58(5):347-354.
85. Rosenthal N.E., Sack D.A., Carpenter C.J., et al. Antidepressant effects of light in seasonal affective disorder. Am J Psychiatry 1985, 142(2):163-170.
86. Shelton R.C., Osuntokun O., Heinloth A.N., et al. Therapeutic options for treatment-resistant depression. CNS Drugs 2010, 24(2):131-161.
87. American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder. 3rd edition (supplement to American Journal of Psychiatry, Volume 167, Number 10, October 2010).